E
Edward O’neill
Researcher at University of Maryland, Baltimore
Publications - 3
Citations - 5632
Edward O’neill is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Zidovudine & HIV and pregnancy. The author has an hindex of 3, co-authored 3 publications receiving 5566 citations.
Papers
More filters
Journal ArticleDOI
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
Edward M. Connor,Rhoda S. Sperling,Richard D. Gelber,Pavel Kiselev,Gwendolyn B. Scott,Mary Jo O'Sullivan,Russell Vandyke,Mohammed Bey,William T. Shearer,Robert L. Jacobson,Eleanor Jimenez,Edward O’neill,Brigitte Bazin,Jean François Delfraissy,Mary Culnane,Robert W. Coombs,Mary Elkins,Jack Moye,Pamela Stratton,James Balsley +19 more
TL;DR: In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six weeks reduced the risk of maternal-infant HIV transmission by approximately two thirds.
Journal ArticleDOI
Reduction of maternal-infant transmission of human immunodeficiency virus 1 with zidovudine treatment
Edward M. Connor,Rhoda S. Sperling,Richard D. Gelber,Pavel Kiselev,Gwendolyn B. Scott,Mary J. O'Sullivan,Russell Vandyke,Mohammed Bey,William T. Shearer,R Jacobson,Eleanor Jimenez,Edward O’neill,Brigitte Bazin,Jean François Delfraissy,Mary Culnane,Robert W. Coombs,Mary Elkins,Jack Moye,Pamela Stratton,James Balsley +19 more
TL;DR: It was shown that AZT decreased the maternal-infant transmission of HIV and helped decrease infant mortality due to the viral infection.
Journal ArticleDOI
Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their Newborns
John S. Lambert,Lynne M. Mofenson,Courtney V Fletcher,J Jr Moye,E. R. Stiehm,W. A. Meyer,G. J. Nemo,B. J. Mathieson,G. Hirsch,C. V. Sapan,L. M. Cummins,E. Jimenez,Edward O’neill,A. Kovacs,A. Stek +14 more
TL;DR: HIVIG is well-tolerated in HIV-infected pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmacokinetics similar to those of other immunoglobulin preparations.